Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
32
PMCB Quote, Financials, Valuation and Earnings
Last price:
$0.72
Seasonality move
:
35.79%
Day range:
$0.68 - $0.78
52-week range:
$0.63 - $1.90
Dividend yield:
0%
P/E ratio:
0.40x
P/S ratio:
239.61x
P/B ratio:
0.21x
Volume:
147.6K
Avg. volume:
7M
1-year change:
-53.89%
Market cap:
$7.5M
Revenue:
--
EPS (TTM):
-$1.31
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PMCB
PharmaCyte Biotech, Inc.
|
-- | -- | -- | -- | -- |
|
AIM
AIM ImmunoTech
|
-- | -$0.09 | -23.08% | -53.85% | $4.50 |
|
CVM
CEL-SCI Corp.
|
-- | -- | -- | -- | $42.50 |
|
FEMY
Femasys, Inc.
|
$1.1M | -$0.10 | 96.01% | -55.5% | $5.17 |
|
KALA
Kala Bio, Inc.
|
-- | -$1.10 | -- | -43.13% | $1.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PMCB
PharmaCyte Biotech, Inc.
|
$0.74 | -- | $7.5M | 0.40x | $0.00 | 0% | 239.61x |
|
AIM
AIM ImmunoTech
|
$0.04 | $4.50 | $2.8M | -- | $0.00 | 0% | 13.27x |
|
CVM
CEL-SCI Corp.
|
$5.06 | $42.50 | $15.4M | -- | $0.00 | 0% | -- |
|
FEMY
Femasys, Inc.
|
$0.63 | $5.17 | $37.1M | -- | $0.00 | 0% | 9.07x |
|
KALA
Kala Bio, Inc.
|
$0.62 | $1.50 | $5.1M | -- | $0.00 | 0% | 7.18x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PMCB
PharmaCyte Biotech, Inc.
|
-- | 1.303 | 0.49% | 9.89x |
|
AIM
AIM ImmunoTech
|
48.41% | 0.745 | 17.25% | 0.71x |
|
CVM
CEL-SCI Corp.
|
37.03% | 0.660 | 33.61% | 2.14x |
|
FEMY
Femasys, Inc.
|
64.91% | 0.114 | 50.55% | 0.49x |
|
KALA
Kala Bio, Inc.
|
140.72% | 2.141 | 263.3% | 0.65x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PMCB
PharmaCyte Biotech, Inc.
|
-- | -$1.4M | -16.43% | -16.43% | -- | -$979.5K |
|
AIM
AIM ImmunoTech
|
$27K | -$4.5M | -219.06% | -256.33% | -9994.29% | -$3.3M |
|
CVM
CEL-SCI Corp.
|
-$960.8K | -$6M | -117.93% | -230.36% | -- | -$4.7M |
|
FEMY
Femasys, Inc.
|
$224.5K | -$3.7M | -180.14% | -606.11% | -500.93% | -$5.6M |
|
KALA
Kala Bio, Inc.
|
-$128K | -$10.7M | -102.67% | -1375.54% | -- | -$10.9M |
PharmaCyte Biotech, Inc. vs. Competitors
-
Which has Higher Returns PMCB or AIM?
AIM ImmunoTech has a net margin of -- compared to PharmaCyte Biotech, Inc.'s net margin of -10571.43%. PharmaCyte Biotech, Inc.'s return on equity of -16.43% beat AIM ImmunoTech's return on equity of -256.33%.
Company Gross Margin Earnings Per Share Invested Capital PMCBPharmaCyte Biotech, Inc.-- -$1.24 $36.1M AIMAIM ImmunoTech77.14% -$0.06 $5.6M -
What do Analysts Say About PMCB or AIM?
PharmaCyte Biotech, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand AIM ImmunoTech has an analysts' consensus of $4.50 which suggests that it could grow by 11066.25%. Given that AIM ImmunoTech has higher upside potential than PharmaCyte Biotech, Inc., analysts believe AIM ImmunoTech is more attractive than PharmaCyte Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PMCBPharmaCyte Biotech, Inc.0 0 0 AIMAIM ImmunoTech1 0 0 -
Is PMCB or AIM More Risky?
PharmaCyte Biotech, Inc. has a beta of 0.038, which suggesting that the stock is 96.158% less volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.760, suggesting its less volatile than the S&P 500 by 23.953%.
-
Which is a Better Dividend Stock PMCB or AIM?
PharmaCyte Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PharmaCyte Biotech, Inc. pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PMCB or AIM?
PharmaCyte Biotech, Inc. quarterly revenues are --, which are smaller than AIM ImmunoTech quarterly revenues of $35K. PharmaCyte Biotech, Inc.'s net income of -$7.4M is lower than AIM ImmunoTech's net income of -$3.7M. Notably, PharmaCyte Biotech, Inc.'s price-to-earnings ratio is 0.40x while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PharmaCyte Biotech, Inc. is 239.61x versus 13.27x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PMCBPharmaCyte Biotech, Inc.239.61x 0.40x -- -$7.4M AIMAIM ImmunoTech13.27x -- $35K -$3.7M
-
Which has Higher Returns PMCB or CVM?
CEL-SCI Corp. has a net margin of -- compared to PharmaCyte Biotech, Inc.'s net margin of --. PharmaCyte Biotech, Inc.'s return on equity of -16.43% beat CEL-SCI Corp.'s return on equity of -230.36%.
Company Gross Margin Earnings Per Share Invested Capital PMCBPharmaCyte Biotech, Inc.-- -$1.24 $36.1M CVMCEL-SCI Corp.-- -$0.76 $25.3M -
What do Analysts Say About PMCB or CVM?
PharmaCyte Biotech, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 707.99%. Given that CEL-SCI Corp. has higher upside potential than PharmaCyte Biotech, Inc., analysts believe CEL-SCI Corp. is more attractive than PharmaCyte Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PMCBPharmaCyte Biotech, Inc.0 0 0 CVMCEL-SCI Corp.1 0 0 -
Is PMCB or CVM More Risky?
PharmaCyte Biotech, Inc. has a beta of 0.038, which suggesting that the stock is 96.158% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.538, suggesting its less volatile than the S&P 500 by 46.183%.
-
Which is a Better Dividend Stock PMCB or CVM?
PharmaCyte Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PharmaCyte Biotech, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PMCB or CVM?
PharmaCyte Biotech, Inc. quarterly revenues are --, which are smaller than CEL-SCI Corp. quarterly revenues of --. PharmaCyte Biotech, Inc.'s net income of -$7.4M is lower than CEL-SCI Corp.'s net income of -$6.1M. Notably, PharmaCyte Biotech, Inc.'s price-to-earnings ratio is 0.40x while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PharmaCyte Biotech, Inc. is 239.61x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PMCBPharmaCyte Biotech, Inc.239.61x 0.40x -- -$7.4M CVMCEL-SCI Corp.-- -- -- -$6.1M
-
Which has Higher Returns PMCB or FEMY?
Femasys, Inc. has a net margin of -- compared to PharmaCyte Biotech, Inc.'s net margin of -575.1%. PharmaCyte Biotech, Inc.'s return on equity of -16.43% beat Femasys, Inc.'s return on equity of -606.11%.
Company Gross Margin Earnings Per Share Invested Capital PMCBPharmaCyte Biotech, Inc.-- -$1.24 $36.1M FEMYFemasys, Inc.30.78% -$0.10 $13M -
What do Analysts Say About PMCB or FEMY?
PharmaCyte Biotech, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Femasys, Inc. has an analysts' consensus of $5.17 which suggests that it could grow by 796.68%. Given that Femasys, Inc. has higher upside potential than PharmaCyte Biotech, Inc., analysts believe Femasys, Inc. is more attractive than PharmaCyte Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PMCBPharmaCyte Biotech, Inc.0 0 0 FEMYFemasys, Inc.1 0 0 -
Is PMCB or FEMY More Risky?
PharmaCyte Biotech, Inc. has a beta of 0.038, which suggesting that the stock is 96.158% less volatile than S&P 500. In comparison Femasys, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock PMCB or FEMY?
PharmaCyte Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Femasys, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PharmaCyte Biotech, Inc. pays -- of its earnings as a dividend. Femasys, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PMCB or FEMY?
PharmaCyte Biotech, Inc. quarterly revenues are --, which are smaller than Femasys, Inc. quarterly revenues of $729.4K. PharmaCyte Biotech, Inc.'s net income of -$7.4M is lower than Femasys, Inc.'s net income of -$4.2M. Notably, PharmaCyte Biotech, Inc.'s price-to-earnings ratio is 0.40x while Femasys, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PharmaCyte Biotech, Inc. is 239.61x versus 9.07x for Femasys, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PMCBPharmaCyte Biotech, Inc.239.61x 0.40x -- -$7.4M FEMYFemasys, Inc.9.07x -- $729.4K -$4.2M
-
Which has Higher Returns PMCB or KALA?
Kala Bio, Inc. has a net margin of -- compared to PharmaCyte Biotech, Inc.'s net margin of --. PharmaCyte Biotech, Inc.'s return on equity of -16.43% beat Kala Bio, Inc.'s return on equity of -1375.54%.
Company Gross Margin Earnings Per Share Invested Capital PMCBPharmaCyte Biotech, Inc.-- -$1.24 $36.1M KALAKala Bio, Inc.-- -$1.07 $21.3M -
What do Analysts Say About PMCB or KALA?
PharmaCyte Biotech, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Kala Bio, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 141.51%. Given that Kala Bio, Inc. has higher upside potential than PharmaCyte Biotech, Inc., analysts believe Kala Bio, Inc. is more attractive than PharmaCyte Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PMCBPharmaCyte Biotech, Inc.0 0 0 KALAKala Bio, Inc.0 2 0 -
Is PMCB or KALA More Risky?
PharmaCyte Biotech, Inc. has a beta of 0.038, which suggesting that the stock is 96.158% less volatile than S&P 500. In comparison Kala Bio, Inc. has a beta of -2.429, suggesting its less volatile than the S&P 500 by 342.929%.
-
Which is a Better Dividend Stock PMCB or KALA?
PharmaCyte Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kala Bio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PharmaCyte Biotech, Inc. pays -- of its earnings as a dividend. Kala Bio, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PMCB or KALA?
PharmaCyte Biotech, Inc. quarterly revenues are --, which are smaller than Kala Bio, Inc. quarterly revenues of --. PharmaCyte Biotech, Inc.'s net income of -$7.4M is higher than Kala Bio, Inc.'s net income of -$7.6M. Notably, PharmaCyte Biotech, Inc.'s price-to-earnings ratio is 0.40x while Kala Bio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PharmaCyte Biotech, Inc. is 239.61x versus 7.18x for Kala Bio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PMCBPharmaCyte Biotech, Inc.239.61x 0.40x -- -$7.4M KALAKala Bio, Inc.7.18x -- -- -$7.6M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
55
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
45
CTEV alert for Jan 2
Claritev Corp. [CTEV] is down 20.7% over the past day.
Sell
47
ASTS alert for Jan 2
AST Spacemobile, Inc. [ASTS] is up 14.94% over the past day.
Buy
60
BIDU alert for Jan 3
Baidu, Inc. [BIDU] is up 15.01% over the past day.
